Depot antipsychotic medication in the treatment of patients with schizophrenia: (1) Meta-review; (2) Patient and nurse attitudes

Health Technology Assessment

Volumn 5, Issue 34, 2001, Pages

  David, A S ^a   Adams, C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BROMPERIDOL DECANOATE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUPENTIXOL DECANOATE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; FLUPHENAZINE ENANTHATE; FLUSPIRILENE; HALOPERIDOL; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; PENFLURIDOL; PERPHENAZINE DECANOATE; PIMOZIDE; PIPOTIAZINE PALMITATE; PIPOTIAZINE UNDECENOATE; PLACEBO; RISPERIDONE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL DECANOATE;

AKATHISIA; BEHAVIOR; CLINICAL TRIAL; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DATA BASE; DEATH; DEPRESSION; DOSE RESPONSE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INJECTION; MENTAL HEALTH; META ANALYSIS; METHODOLOGY; MOTOR DYSFUNCTION; NURSE; OUTCOMES RESEARCH; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT SATISFACTION; RATING SCALE; RELAPSE; REVIEW; SCHIZOPHRENIA; STATISTICAL ANALYSIS; TABLET FORMULATION; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREMOR; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 17044452043     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta5340     Document Type: Review

References (74)

1. Schizophrenia: Manifestations, incidence and course in different cultures. A World Health Organization-ten country study
2. The cost of relapse in schizophrenia
3. Insight and compliance
4. Determinants of medication compliance in schizophrenia: Empirical and clinical findings
5. A brief history of depot neuroleptics
6. Depot antipsychotic drugs: Place in therapy
7. Long term depot antipsychotics. A risk-benefit assessment
8. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia
9. Depot neuroleptics therapy: An underutilized treatment option
10. Depot neuroleptics in relapse prevention: Advantages and disadvantages
11. Guidelines for depot antipsychotic treatment in schizophrenia
12. Long-term depot maintenance of chronic schizophrenic outpatients: The seven-year follow-up of the MRC fluphenazine/placebo trial
13. Depot bromperidol decanoate for schizophrenia
14. Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders
15. Depot fluphenazine for schizophrenia
16. Depot fluspirilene for schizophrenia
17. Depot haloperidol decanoate for schizophrenia
18. Depot perphenazine decanoate and enanthate for schizophrenia
19. Depot pipothiazine palmitate and undecylenate for schizophrenia
20. Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses
21. Cochrane Collaboration handbook
22. In defence of the depot clinic. The consumers' opinion
23. A survey of the attitudes of chronic psychiatric patients living in the community toward their medication
24. Methodology and reports of systematic reviews and meta-analyses: A comparison of Cochrane reviews with articles published in paper-based journals
25. A standardised psychiatric assessment scale for rating psychotic patients
26. A comprehensive psychopathological rating scale
27. NOSIE-30: A treatment sensitive ward behavior scale
28. Extra-pyramidal symptom rating scale
29. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients
30. A rating scale for extrapyramidal side effects
31. Clinical characteristics, health beliefs and compliance with maintenance treatment: A comparison between regular and irregular attenders at a depot clinic
32. Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics
33. Switching from depot antipsychotics to risperidone: Results of a study of chronic schizophrenia
34. Patient requests and attitude towards neuroleptics
35. How does the psychiatric patient feel about depot treatment, compulsion or help?
36. Depot clinic: Consumers' viewpoint
37. Patients' knowledge and views of their depot neuroleptic medication
38. Developing practice through clinical audit
39. Long-term in depot clinics and patients' rights: An issue for assertive outreach
40. Psykologiska aspekter på depåbehandling vid schizofrena syndrom
41. Depot injections at home or clinic? Letting clients choose
42. Involving users in developing phenothiazine services
43. Patients' opinions concerning side effects of depots neuroleptics
44. Assessing the side-effects of antipsychotic drugs: A survey of CPN practice
45. Randomized controlled trial of teaching practice nurses to carry out structured assessments of patients receiving depot antipsychotic injections
46. Practice nurse involvement in giving depot neuroleptic injections: Development of a patient assessment and monitoring checklist
47. Management of depot neuroleptics
48. Content and quality of 2000 controlled trials in schizophrenia over 50 years
49. The use of fluphenazines in a continuing-care programme
50. Depot neuroleptics: Cost-effective and underutilised
51. Gesamtkrankenkosten der Schizophrenie und monetare bewertung einer rezidivprophylaxe am beispiel eines standard-depot-neuroleptikums (Flupentixoldecanoat)
52. A mirror image outpatient study at a depot phenothiazine clinic
53. Reducing hospital readmission rates among schizophrenics
54. Cost-benefit of a depot neuroleptic clinic: 10 years' follow-up of functioning of a clinical-administrative model
55. Comparison of conventional neuroleptic therapy with depot neuroleptics. An attempt at economic evaluation
56. Rehospitalisation rates for depot antipsychotics and pharmacoeconomic implications: Comparison with risperidone
57. A pharmacoeconomic model of outpatient antipsychotic therapy in 'revolving door' schizophrenic patients
58. Comparison of direct treatment costs for schizophrenia using oral or depot neuroleptics: A pharmacoeconomic analysis
59. Costs and benefits of two doses of fluphenazine
60. Costs of schizophrenia
61. Burden on the families of patients with schizophrenia
62. Homicides by people with mental illness: Myth and reality
63. Economics and schizophrenia: The real cost
64. Excess mortality of mental disorder
65. Improving the quality of randomized controlled trials. The CONSORT statement
66. Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics: Attitudes to medication and insight
67. Non-compliance with antipsychotic depot medication: User's views on advantages and disadvantages